<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Total anomalous pulmonary venous connection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Total anomalous pulmonary venous connection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Total anomalous pulmonary venous connection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brian D Soriano, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David R Fulton, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John K Triedman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 15, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Total anomalous pulmonary venous connection (TAPVC), also referred to as total anomalous pulmonary venous return (TAPVR), is a cyanotic congenital defect in which all four pulmonary veins fail to make their normal connection to the left atrium. This results in drainage of all pulmonary venous return into the systemic venous circulation.</p><p>The anatomic variants, clinical manifestations, diagnosis, and management of TAPVC will be reviewed here. Partial anomalous pulmonary venous connection (PAPVC) is discussed separately. (See  <a class="medical medical_review" href="/d/html/5764.html" rel="external">"Partial anomalous pulmonary venous return"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">INCIDENCE</span><span class="headingEndMark"> — </span>The incidence of TAPVC ranges from 0.6 to 1.2 per 10,000 live births [<a href="#rid1">1,2</a>]. Among newborns with congenital heart disease, the incidence of TAPVC ranges between 0.7 and 1.5 percent.</p><p class="headingAnchor" id="H3"><span class="h1">EMBRYOLOGY</span><span class="headingEndMark"> — </span>In normal development, the lung buds are formed from the primitive foregut and share a common vascular plexus (splanchnic plexus), which initially drains into the common cardinal and umbilicovitelline venous systems. With the formation of the lungs (27 to 29 days of gestation), a portion of the splanchnic plexus differentiates into the primitive pulmonary vascular bed [<a href="#rid3">3,4</a>]. During this same time period, the primitive left atrium forms a primordial evagination (common pulmonary vein) that grows into and joins the pulmonary portion of the splanchnic plexus. Once the connection is made, the primitive pulmonary venous system separates from the cardinal and umbilicovitelline veins. Portions of the common pulmonary vein are subsequently incorporated into the wall of the left atrium and become the two right and two left pulmonary veins, each of which enters the left atrium through a separate orifice.</p><p>TAPVC arises from the failure of the left atrium to link with the pulmonary venous plexus, which results in the retention of connections through the primitive cardinal and umbilicovitelline drainage pathways. The anatomic variants of TAPVC are dependent upon which specific connections are retained. The cardinal venous system provides connections to the innominate vein, right atrium, superior vena cava, or azygous vein and the umbilicovitelline system to the portal or hepatic vein, or inferior vena cava.</p><p class="headingAnchor" id="H4"><span class="h1">ANATOMY</span><span class="headingEndMark"> — </span>TAPVC can be divided into four anatomic types based on the location of the connections relative to the heart  (<a class="graphic graphic_figure graphicRef77375" href="/d/graphic/77375.html" rel="external">figure 1</a>) [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supracardiac</strong> – Supracardiac TAPVC results from retained pulmonary vein connections to the cardinal venous systems. In affected patients, the pulmonary veins from both lungs course to a confluent chamber that is located just posterior to the left atrium. From this chamber, blood ascends through a vertically oriented vein that most often connects to the left innominate vein. Other locations for supracardiac TAPVC connections include the right-sided superior vena cava, azygous vein, or a persistent left superior vena cava, which would drain to the right atrium via the coronary sinus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac</strong> – Cardiac TAPVC results from retained pulmonary vein connections to the cardinal venous systems. In affected patients, the pulmonary veins course directly toward the heart, but instead of the normal linkage within the left atrium, the pulmonary veins connect to the posterior aspect of the coronary sinus or to the right atrium itself  (<a class="graphic graphic_movie graphicRef76860" href="/d/graphic/76860.html" rel="external">movie 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infracardiac</strong> – Infracardiac TAPVC results from retained pulmonary vein connections to the umbilicovitelline venous system. In affected patients, the pulmonary veins drain into a common vertical vein that courses inferiorly from the mediastinum, through the diaphragm via the esophageal hiatus, and inserts most often into the portal vein [<a href="#rid3">3,6</a>]. Other insertions include the hepatic vein, ductus venosus, or inferior vena cava either above or below the level of the diaphragm [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mixed</strong> – Mixed TAPVC refers to any combination of connections that enter at two or more different levels  (<a class="graphic graphic_movie graphicRef65581" href="/d/graphic/65581.html" rel="external">movie 2</a>). The most common arrangement of mixed TAPVC is that of three pulmonary veins joining to form a single confluence and a fourth vein draining via a separate venous connection [<a href="#rid8">8</a>].</p><p></p><p>In the available case series, the relative frequencies of these four variants were as follows [<a href="#rid9">9,10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Supracardiac – 45 to 50 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac – 15 to 20 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Infracardiac – 20 to 25 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Mixed – Approximately 10 percent</p><p></p><p class="headingAnchor" id="H5"><span class="h1">PHYSIOLOGY</span><span class="headingEndMark"> — </span>Key physiologic factors that impact the timing of presentation and degree of symptoms in infants with TAPVC include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Venous mixing</strong> – In patients with TAPVC, the entire oxygenated pulmonary venous return mixes with deoxygenated blood from the systemic venous system. In supracardiac and infracardiac TAPVC, mixing of the blood occurs where the pulmonary veins join the systemic veins before the return to the heart. In cardiac TAPVC, the mixing occurs either within or just adjacent to the right atrium.</p><p></p><p class="bulletIndent1">The mixed, partially oxygenated blood is then shunted right-to-left at the atrial level (or infrequently through a patent ductus arteriosus) into the systemic circulation, resulting in cyanosis.</p><p></p><p class="bulletIndent1">Because the right atrium is receiving blood from both the pulmonary and systemic venous systems, both the right atrium and ventricle become dilated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary venous obstruction</strong> – In obstructed forms of TAPVC, there is significant obstruction of pulmonary venous return to the heart. When this occurs, pulmonary venous pressure rises and the high pressure is transmitted back to the lung vasculature, resulting in progressive interstitial and alveolar edema. These changes, in turn, lead to increased pulmonary vascular resistance and elevated pulmonary artery pressure (ie, pulmonary hypertension). In some cases, pulmonary artery pressure can exceed systemic pressure, resulting in right ventricular dilation, hypertrophy, and right heart failure.</p><p></p><p class="bulletIndent1">Pulmonary venous obstruction can occur at different levels:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Supracardiac – Obstruction may occur where the vertical vein courses between the left pulmonary artery and left mainstem bronchus.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infracardiac – Obstruction usually occurs in cases of infracardiac TAPVC. Constriction of the vertical vein commonly occurs at the level of the diaphragm, within the liver in cases where the connection involves the ductus venous, or by the liver parenchyma when the connection is with the portal vein.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiac – In some cases of cardiac TAPVC, obstructed flow may be due to stenosis at the mouth of the coronary sinus where the pulmonary veins connect.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other – Other sources of obstruction include stenotic, tortuous, or atretic pulmonary and common vertical veins, or a restrictive atrial septum.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Left-to-right shunting</strong> – In unobstructed forms of TAPVC, there is no significant stenosis or compression of the pulmonary veins or the venous confluence. Unobstructed forms typically have a net left-to-right shunt due to the relatively low resistance in the lungs. The pulmonary bed thus receives a disproportionate amount of stroke volume from the heart, leading to pulmonary overcirculation. Due to the high amount of pulmonary blood flow, pulmonary artery pressures in the unobstructed forms are usually elevated, though not as severely as the obstructed forms. If uncorrected, this will lead to right ventricular hypertrophy and pulmonary vascular changes that may result in right ventricular failure. (See  <a class="medical medical_review" href="/d/html/5773.html" rel="external">"Pathophysiology of left-to-right shunts"</a>.)</p><p></p><p class="headingAnchor" id="H3753531865"><span class="h1">NATURAL HISTORY</span><span class="headingEndMark"> — </span>The natural history of TAPVC depends upon the severity of obstruction and the size of the interatrial communication. In general, the outcome without treatment is poor, with a mortality rate of 80 percent by one year of age [<a href="#rid11">11,12</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Severe obstruction – Patients who present in the first few days of life with severe pulmonary obstruction usually die within the first month without surgical intervention.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Restrictive interatrial communication – Without surgery or palliative intervention with cardiac catheterization, patients with limited interatrial communication (restrictive atrial septum) have a mortality rate of approximately 80 percent in the first year of life. These patients develop severe heart failure, failure to thrive, and recurrent pulmonary infections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unobstructed disease and large interatrial communication – The natural course of uncorrected patients with unobstructed TAPVC and sufficient interatrial communication varies. Some patients may have only mild symptoms with exertion, but most develop progressive right heart failure and pulmonary vascular disease due to pulmonary overcirculation. (See  <a class="medical medical_review" href="/d/html/17234.html" rel="external">"Pulmonary hypertension in children: Classification, evaluation, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H9"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H4235174176"><span class="h2">Presentation</span><span class="headingEndMark"> — </span>The clinical manifestations vary and are dependent upon the presence and degree of pulmonary venous obstruction (PVO). In general, the more severe the obstruction, the earlier and more severe the presentation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obstructed TAPVC</strong> – Patients with severe obstruction generally present as critically ill newborns with profound cyanosis, respiratory failure, and shock. These patients are more likely to have infracardiac TAPVC anatomy [<a href="#rid13">13</a>]. Obstructed TAPVC results in elevated pulmonary artery pressure, pulmonary edema, respiratory distress, diminished systemic output, and hypotension. In the preterm newborn, obstructed TAPVC may be difficult to distinguish from respiratory distress syndrome (RDS). (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unobstructed TAPVC</strong> – Patients with unobstructed lesions may only have subtle cyanosis immediately after birth, which may be detected with pulse oximetry screening. Although hypoxia is invariably present in unobstructed TAPVC, the degree can vary, and some patients may not appear to be cyanotic. In one series of 75 patients with TAPVC, two appeared to be acyanotic yet oxygen saturations (SaO<sub>2</sub>) measured by cardiac catheterization were 88 and 92 percent, respectively [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/101291.html" rel="external">"Newborn screening for critical congenital heart disease using pulse oximetry"</a>.)</p><p></p><p class="bulletIndent1">After the immediate newborn period, symptoms are related to pulmonary overcirculation, including tachypnea, poor feeding, and failure to thrive. Over time, these patients develop right ventricular hypertrophy and pulmonary vascular changes that may result in right ventricular failure.</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The physical examination varies with the degree of obstruction and the degree of shunting.</p><p>In patients with unobstructed TAPVC, physical findings are associated with the amount of left-to-right shunting and are similar to those seen in patients with an atrial septal defect. These include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Fixed split second heart sound (S<sub>2</sub>) due to right ventricular overload  (<a class="graphic graphic_movie graphicRef104783" href="/d/graphic/104783.html" rel="external">movie 3</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Systolic ejection murmur due to increased stroke volume across the pulmonary valve  (<a class="graphic graphic_movie graphicRef104783" href="/d/graphic/104783.html" rel="external">movie 3</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Diastolic rumble due to increased flow across the tricuspid valve  (<a class="graphic graphic_movie graphicRef104794" href="/d/graphic/104794.html" rel="external">movie 4</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatomegaly due to right-sided failure</p><p class="bulletIndent1"><span class="glyph">●</span>Tachypnea</p><p class="bulletIndent1"><span class="glyph">●</span>Variable degrees of cyanosis</p><p></p><p>Patients with obstructed TAPVC have physical findings that include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>S<sub>2</sub> is prominent</p><p class="bulletIndent1"><span class="glyph">●</span>Ejection murmurs are less frequent than in unobstructed TAPVC</p><p class="bulletIndent1"><span class="glyph">●</span>A soft, continuous murmur may be detected across the anomalous vertical vein with close auscultation over the area of obstruction</p><p class="bulletIndent1"><span class="glyph">●</span>Cyanosis</p><p class="bulletIndent1"><span class="glyph">●</span>Cool extremities</p><p class="bulletIndent1"><span class="glyph">●</span>Hypotension and diminished pulses may be noted if there is severe obstruction </p><p class="bulletIndent1"><span class="glyph">●</span>Hepatomegaly due to direct venous congestion in cases of obstructed infracardiac lesions</p><p class="bulletIndent1"><span class="glyph">●</span>Tachypnea</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Other congenital anomalies</span><span class="headingEndMark"> — </span>Although TAPVC can occur as an isolated cardiac lesion, it also is associated with other complex congenital heart lesions (eg, functional single ventricles) or visceroatrial situs abnormalities. There is an increased incidence in heterotaxy patients diagnosed with asplenia or right atrial isomerism.</p><p>TAPVC is a common finding in patients who have heterotaxy with asplenia or polysplenia [<a href="#rid15">15</a>]. In these patients, it is presumed that disruption of both cardiac and abdominal viscera early in embryology result in the characteristic congenital anomalies of this syndrome. (See  <a class="medical medical_review" href="/d/html/14557.html" rel="external">"Heterotaxy (isomerism of the atrial appendages): Anatomy, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H3747903417"><span class="h2">Electrocardiography and chest radiography findings</span><span class="headingEndMark"> — </span>Findings on electrocardiography (ECG) and chest radiography are variable, nonspecific, and can depend upon the presence and severity of obstruction.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>ECG</strong> – Findings on ECG are both insensitive and nonspecific and cannot be used to make a diagnosis of TAPVC. They include evidence of right ventricular hypertrophy [<a href="#rid14">14</a>]. However, in neonates, it is sometimes difficult to differentiate pathologic right ventricular hypertrophy from the physiologic increase in right-sided voltage normally seen during the newborn period. Tall P waves indicating right atrial enlargement may be commonly seen in patients greater than one month of age. Conduction abnormalities usually are not present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest radiography</strong> – In patients with unobstructed TAPVC, lung parenchyma may be normal except for mild prominence of the pulmonary arteries. The heart size is mildly enlarged. The classic snowman sign is present in young children with supracardiac TAPVC  (<a class="graphic graphic_diagnosticimage graphicRef50639" href="/d/graphic/50639.html" rel="external">image 1</a>) but is usually masked by the thymic shadow in neonates. In patients with obstructed TAPVC, the cardiac silhouette is not enlarged. Pulmonary vein congestion and interstitial edema may be present, and in many cases, pulmonary artery dilation is also present. In severe obstruction, the combination of vascular congestion and pulmonary edema leads to a ground glass appearance  (<a class="graphic graphic_diagnosticimage graphicRef103884" href="/d/graphic/103884.html" rel="external">image 2</a>).</p><p></p><p class="headingAnchor" id="H12"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of TAPVC is generally made by echocardiography. TAPVC is one of three diagnoses that should be suspected in infants presenting with cyanotic congenital heart disease and clinical evidence of pulmonary overcirculation. The other two are transposition of the great arteries and truncus arteriosus, which are discussed separately. (See  <a class="medical medical_review" href="/d/html/5780.html" rel="external">"Cardiac causes of cyanosis in the newborn"</a> and  <a class="medical medical_review" href="/d/html/14374.html" rel="external">"D-transposition of the great arteries (D-TGA): Anatomy, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/14588.html" rel="external">"Truncus arteriosus"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Echocardiography</span><span class="headingEndMark"> — </span>The diagnosis of TAPVC is made based upon a composite of findings, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Right-to-left interatrial shunting</p><p class="bulletIndent1"><span class="glyph">●</span>Demonstration of a common ascending collecting vein along with a dilated superior vena cava and innominate vein (because of increased blood flow) in patients with supracardiac lesions</p><p class="bulletIndent1"><span class="glyph">●</span>Demonstration of a common descending collecting vein with a connection to either the hepatic or portal vein, and a dilated inferior vena cava (because of increased blood flow) in patients with infracardiac lesions</p><p class="bulletIndent1"><span class="glyph">●</span>Demonstration of a direct connection between the pulmonary venous system and the right atrium or coronary sinus in patients with cardiac TAPVC  (<a class="graphic graphic_movie graphicRef76860" href="/d/graphic/76860.html" rel="external">movie 1</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>In all forms of TAPVC, the right atrium and ventricle will be dilated</p><p class="bulletIndent1"><span class="glyph">●</span>Inability to demonstrate the normal pulmonary venous connections to the left atrium</p><p class="bulletIndent1"><span class="glyph">●</span>Doppler imaging can also estimate pulmonary artery pressures and measure the blood flow rates through the ascending or descending vertical veins</p><p></p><p>The diagnostic accuracy of echocardiography was illustrated in a case series that reported that 22 of 23 patients with TAPVC were accurately diagnosed [<a href="#rid16">16</a>]. The sites of connection of the individual pulmonary veins were identified in all but one patient.</p><p>Prenatal diagnosis of TAPVC is challenging [<a href="#rid17">17,18</a>]. In a single-center retrospective study of 137 cases, 12 percent of the 137 cases were diagnosed prenatally [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Other imaging studies</span><span class="headingEndMark"> — </span>Though echocardiography can establish the diagnosis of TAPVC in most cases, imaging with computed tomographic angiography [CTA], magnetic resonance angiography [MRA], or cardiac catheterization is sometimes needed to provide additional detail.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CTA and MRA</strong> – CTA and MRA are typically reserved for cases when the initial echocardiogram could not completely resolve the anatomy or was unable to identify the individual pulmonary veins and vertical veins, which are important for surgical planning. Both CTA and MRA can evaluate pulmonary pathways and connections in great detail [<a href="#rid19">19-21</a>]. CTA better visualizes lung parenchyma and airways; however, it requires exposure to ionizing radiation, while MRA does not. MRA has the disadvantages of requiring more time to image with spatial resolution that is inferior to CTA. Infants and young children often need sedation for this modality. Both CTA and MRA require intravenous contrast for optimal visualization of the vasculature. In patients with renal failure or insufficiency, certain vessels can be visualized without intravenous contrast, but image quality may vary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac catheterization</strong> – Although cardiac catheterization was previously the gold standard for diagnosis of TAPVC, it is generally not needed to make the diagnosis. Other less invasive and less costly diagnostic modalities (ie, echocardiography, CTA, and MRA) have generally replaced cardiac catheterization. However, cardiac catheterization may be indicated if more hemodynamic information is required or in rare patients who may require palliative interventional procedures, such as atrial septostomy to improve interatrial blood flow in those with a restrictive atrial septum. (See <a class="local">'Management'</a> below.)</p><p></p><p class="headingAnchor" id="H784627460"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of TAPVC includes other conditions that present with cyanosis and respiratory distress in the neonatal period:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obstructed TAPVC</strong> – Patients with severe obstruction generally present as critically ill newborns with cyanosis and with symptoms of respiratory failure and shock. TAPVC may be difficult to distinguish from respiratory distress syndrome (RDS), persistent pulmonary hypertension of the newborn (PPHN), or septic shock. (See  <a class="medical medical_review" href="/d/html/4964.html" rel="external">"Overview of neonatal respiratory distress and disorders of transition"</a> and  <a class="medical medical_review" href="/d/html/5055.html" rel="external">"Respiratory distress syndrome (RDS) in the newborn: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5045.html" rel="external">"Persistent pulmonary hypertension of the newborn (PPHN): Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">The timing of the onset of symptoms can help differentiate TAPVC from RDS. Signs of RDS begin immediately after birth, whereas the presentation of TAPVC is slightly delayed, with onset of symptoms typically appearing after the first 12 hours of life [<a href="#rid22">22</a>]. Ultimately, echocardiography is required to make the correct diagnosis. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unobstructed TAPVC</strong> – Patients with unobstructed lesions may only have subtle cyanosis immediately after birth, which may be detected by a pulse oximetry screening. The approach to evaluating cyanosis in newborns is discussed separately. (See  <a class="medical medical_review" href="/d/html/14305.html" rel="external">"Approach to cyanosis in the newborn"</a> and  <a class="medical medical_review" href="/d/html/5780.html" rel="external">"Cardiac causes of cyanosis in the newborn"</a>.)</p><p></p><p class="bulletIndent1">After the immediate newborn period, symptoms of unobstructed TAPVC include tachypnea, poor feeding, and failure to thrive. The clinical findings are similar to other disorders with large left-to-right shunts, such as a large ventricular or atrial septal defect. TAPVC is distinguished from these with echocardiography. (See  <a class="medical medical_review" href="/d/html/5754.html" rel="external">"Isolated atrial septal defects (ASDs) in children: Classification, clinical features, and diagnosis", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/d/html/5787.html" rel="external">"Isolated ventricular septal defects (VSDs) in infants and children: Anatomy, clinical features, and diagnosis", section on 'Clinical features'</a>.)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H19"><span class="h2">Initial medical management</span><span class="headingEndMark"> — </span>Initial medical management of TAPVC depends upon the degree of obstruction:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obstructed TAPVC</strong> – Patients with severe obstructed TAPVC present as critically ill neonates. Initial medical management is focused on stabilizing these patients prior to surgery. This may include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Supplemental oxygen. (See  <a class="medical medical_review" href="/d/html/5067.html" rel="external">"Respiratory support, oxygen delivery, and oxygen monitoring in the newborn"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mechanical ventilation. (See  <a class="medical medical_review" href="/d/html/5032.html" rel="external">"Overview of mechanical ventilation in neonates"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inotropic support.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prostaglandin E1 (<a class="drug drug_pediatric" data-topicid="13353" href="/d/drug information/13353.html" rel="external">alprostadil</a>) therapy may be needed to prevent closure of the ductus arteriosus, which may help maintain systemic cardiac output. However, a patent ductus arteriosus may also increase the degree of cyanosis. (See  <a class="medical medical_review" href="/d/html/5785.html" rel="external">"Diagnosis and initial management of cyanotic heart disease in the newborn", section on 'Prostaglandin E1'</a>.)</p><p></p><p class="bulletIndent1">In some cases, the above medical management fails to stabilize the patient. In these patients, additional interventions include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Extracorporeal membrane oxygenation (ECMO) – ECMO has been used when medical management is unable to correct severe hypoxemia, acidosis, and hemodynamic instability [<a href="#rid23">23-25</a>]. This has allowed surgical correction to be performed even in the most severely ill patients. Postoperatively, continued ECMO may be needed in cases with severe persistent pulmonary hypertension.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Palliative cardiac catheterization procedures – Temporizing cardiac catheterization procedures include atrial septostomy in patients with restrictive interatrial blood flow [<a href="#rid25">25</a>] and stent placements into severely obstructed pulmonary and common vertical veins [<a href="#rid26">26</a>]. These measures are used to stabilize patients prior to surgical correction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unobstructed TAPVC</strong> – Patients with unobstructed TAPVC typically present after the immediate newborn period with signs of heart failure. Initial medical management for these infants consists of diuretic therapy (eg, with <a class="drug drug_pediatric" data-topicid="13329" href="/d/drug information/13329.html" rel="external">furosemide</a>) and other supportive measures as needed. (See  <a class="medical medical_review" href="/d/html/14520.html" rel="external">"Heart failure in children: Management", section on 'Diuretics'</a> and  <a class="medical medical_review" href="/d/html/14520.html" rel="external">"Heart failure in children: Management", section on 'General measures'</a>.)</p><p></p><p class="headingAnchor" id="H20"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>Surgical correction is indicated in all patients with TAPVC, regardless of the degree of obstruction, because the prognosis without surgery is generally poor. (See <a class="local">'Natural history'</a> above.)</p><p>Surgery should be performed once the diagnosis is made and the patient is stabilized. As previously discussed, in some instances of severely obstructed TAPVC, it is difficult to stabilize the patient and interventions such as emergency surgical correction or ECMO are needed. (See <a class="local">'Initial medical management'</a> above.)</p><p>The goal of surgery is to reestablish a direct pathway between the pulmonary veins and the left atrium, while at the same time avoiding obstruction of pulmonary venous drainage. The surgical approach is via a median sternotomy and is performed under cardiopulmonary bypass with circulatory arrest. The specific surgical procedure varies depending upon the anatomy of the TAPVC lesion.</p><p class="bulletIndent1"><span class="glyph">●</span>In supra- and infracardiac TAPVC with a common vertical vein, a normal pulmonary venous pathway is created by opening and forming an anastomosis between the pulmonary venous confluence and the left atrium. The vertical vein is then ligated and divided.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In cases where the pulmonary veins drain directly into the superior vena cava, an intracardiac baffle is usually formed to channel the blood from the right atrium across the atrial septum into the left atrium.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In cardiac TAPVC to the coronary sinus, the partition between the coronary sinus and left atrium is incised or excised and a patch is used to close any atrial septal defect between the left atrium and right atrium. With this procedure, both pulmonary vein and coronary vein flow returns to the left atrium.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In infracardiac TAPVC that drains close to the right atrium, an anastomosis is created between the pulmonary venous confluence with reconstruction of the interatrial septum to direct blood flow from the pulmonary veins directly to the left atrium.</p><p></p><p class="headingAnchor" id="H21"><span class="h1">OUTCOME</span></p><p class="headingAnchor" id="H22"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>With improved medical management, surgical management, and the use of extracorporeal membrane oxygenation (ECMO) to support the most severely affected neonates, the survival rate has improved so that most patients with isolated TAPVC survive into adulthood [<a href="#rid13">13,27-32</a>]. Overall, early mortality (death within 30 days of surgical correction) is &lt;10 percent, and late mortality is approximately 5 percent. Long-term survival to adolescence is approximately 85 percent.</p><p>Reported risk factors associated with mortality include [<a href="#rid10">10,27,33-35</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Small pulmonary vein and confluence size</p><p class="bulletIndent1"><span class="glyph">●</span>Coexisting cardiac anomalies, such as single-ventricle physiology</p><p class="bulletIndent1"><span class="glyph">●</span>Younger age at operation</p><p class="bulletIndent1"><span class="glyph">●</span>Need for emergency repair (hospital admission on day 0 or 1)</p><p class="bulletIndent1"><span class="glyph">●</span>Increased total bypass and circulatory arrest time</p><p class="bulletIndent1"><span class="glyph">●</span>Postoperative pulmonary hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary venous obstruction (PVO)</p><p></p><p class="headingAnchor" id="H24"><span class="h2">Morbidity</span><span class="headingEndMark"> — </span>Long-term complications following repair of TAPVC in infancy may include recurrent PVO, cardiac arrhythmias, neurodevelopmental delays, and growth delay.</p><p>Patients with associated complex cardiac anomalies have increased morbidity compared with those with isolated TAPVC. In the previously mentioned prospective study, patients with associated complex cardiac anomalies commonly require chronic cardiac medications and additional hospitalizations for cardiac care during 4.5 years of follow-up after surgery, whereas these were rare among children with isolated TAPVC [<a href="#rid36">36</a>]. In addition, children with associated cardiac anomalies were more likely to have growth delays, whereas children with isolated TAPVC had normal growth.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PVO</strong> – PVO can be extrinsic (eg, vertical vein obstruction in unrepaired supracardiac TAPVC) or intrinsic (spontaneous stenosis of one or more pulmonary veins). Patients with preoperative PVO are at risk for recurrent PVO after surgery, and this appears to convey an increased risk of morbidity and mortality (both early and late) [<a href="#rid10">10,27,34</a>]. In the available case series, approximately 15 percent of patients had postoperative PVO requiring intervention [<a href="#rid3">3,10</a>]. In one multicenter study of 422 live-born cases, mortality at three years after surgery was considerably higher in patients with postoperative PVO compared with the overall cohort (41 versus 15 percent, respectively) [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1">In a series of 65 patients who underwent repair of isolated TAPVC at a single institution, 60 percent had preoperative PVO, of whom 18 percent had recurrent PVO postoperatively [<a href="#rid34">34</a>]. Mortality among patients with recurrent PVO was 57 percent, with most deaths occurring late (ranging from 61 to 356 days after surgery). By contrast, there were no deaths among patients without preoperative PVO.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reoperation</strong> – In the available case series, approximately 10 to 15 percent of patients with isolated TAPVC required reoperation primarily due to stenosis of individual pulmonary vein(s) or the surgical anastomosis [<a href="#rid10">10,27-32,36</a>]. If restenosis does not occur within one year after surgical repair, reoperation is rarely required [<a href="#rid30">30,37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arrhythmias</strong> – Several case series have noted an increased risk of arrhythmias, especially sinus node dysfunction [<a href="#rid38">38,39</a>]. This may be due to disruption of the conduction system by the atrial incision used to repair TAPVC. (See  <a class="medical medical_review" href="/d/html/5759.html" rel="external">"Bradycardia in children", section on 'Sinus node dysfunction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Developmental outcomes </strong>– Neurocognitive outcomes were evaluated in a prospective follow-up study of 67 infants with TAPVC who underwent repair in the neonatal period [<a href="#rid36">36</a>]. Developmental scores at 4.5 years of age were in the low-normal range for patients with isolated TAPVC (mean full-scale intelligence quotient [IQ] 92±18) but were lower in patients with associated complex cardiac anomalies (mean full-scale IQ 81±10). In another single-center retrospective study of 30 children who had undergone TAPVC repair in infancy and were later assessed at school age (mean age 11 years), scores on standardized neurodevelopmental tests were lower than population norms [<a href="#rid40">40</a>]. Fine motor function, visual-motor integration, and attention are the most commonly affected domains.</p><p></p><p class="headingAnchor" id="H25"><span class="h1">FOLLOW-UP CARE</span><span class="headingEndMark"> — </span>After surgical repair of TAPVC, follow-up care should be individually planned through the primary caregiver in collaboration with a pediatric cardiologist, who should be involved in periodic follow-up evaluations.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical activity</strong> – In the absence of residual pulmonary vein stenosis or pulmonary hypertension, exercise tolerance is generally normal in children with repaired TAPVC, regardless of the anatomic subtype. Physical activities and sports participation should not be restricted. (See  <a class="medical medical_review" href="/d/html/95296.html" rel="external">"Physical activity and exercise in patients with congenital heart disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimicrobial prophylaxis</strong> – Infective endocarditis prophylaxis precautions should be considered within the first six months after surgical repair, after which it is no longer required. (See  <a class="medical medical_review" href="/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Developmental screening</strong> – Children with TAPVC should undergo appropriate surveillance, screening, and/or referral for neurodevelopmental impairment [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/615.html" rel="external">"Developmental-behavioral surveillance and screening in primary care"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arrhythmia screening</strong> – Periodic screening for arrhythmias is not routinely recommended in asymptomatic children with repaired TAPVC. Because of the known association between intracardiac surgical repairs and atrial arrhythmias, however, periodic Holter monitoring may be considered in asymptomatic adolescents.</p><p></p><p class="headingAnchor" id="H1709456637"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115414.html" rel="external">"Society guideline links: Congenital heart disease in infants and children"</a>.)</p><p class="headingAnchor" id="H23222264"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/85377.html" rel="external">"Patient education: Total anomalous pulmonary venous connection in children (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H26"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anatomy</strong> – Total anomalous pulmonary venous connection (TAPVC) is a form of cyanotic congenital heart disease in which the four pulmonary veins fail to make their normal connection to the left atrium and all drain into the systemic venous circulation through various anatomic pathways. (See <a class="local">'Introduction'</a> above and <a class="local">'Embryology'</a> above.)</p><p></p><p class="bulletIndent1">The four anatomic variants of TAPVC are defined by the location of their connection relative to the heart: supracardiac, cardiac, infracardiac, and mixed TAPVC  (<a class="graphic graphic_figure graphicRef77375" href="/d/graphic/77375.html" rel="external">figure 1</a>). (See <a class="local">'Anatomy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physiology</strong> – In TAPVC, the entire oxygenated pulmonary venous return mixes with the systemic venous system. A portion of this mixed, partially oxygenated blood is then shunted right-to-left at the atrial level (or infrequently through a patent ductus arteriosus) into the systemic arterial circulation, causing cyanosis. (See <a class="local">'Physiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation </strong>– The clinical presentation varies and is dependent upon the presence and degree of pulmonary venous obstruction (PVO). (See <a class="local">'Presentation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Obstructed TAPVC – Patients with severe obstruction generally present as critically ill newborn infants with cyanosis, respiratory distress, and signs of shock.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unobstructed TAPVC – Those with unobstructed lesions may only have subtle cyanosis immediately after birth, which may be detected by a pulse oximetry screening. After the immediate newborn period, symptoms are related to pulmonary overcirculation, including tachypnea, poor feeding, and failure to thrive. Over time, these patients develop right ventricular hypertrophy and pulmonary vascular changes that may result in right ventricular failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis of TAPVC is usually made by cardiac echocardiography. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial medical management</strong> – Initial medical management focuses on stabilizing patients prior to surgical correction (see <a class="local">'Initial medical management'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with <strong>obstructed</strong> TAPVC typically present as critically ill with severe respiratory failure and/or shock. Management includes supplemental oxygen, mechanical ventilation, administration of inotropic drugs, and in some cases, prostaglandin E1 (<a class="drug drug_pediatric" data-topicid="13353" href="/d/drug information/13353.html" rel="external">alprostadil</a>) therapy. If initial medical management does not adequately stabilize the patient, extracorporeal membrane oxygenation (ECMO) and palliative cardiac catheterization procedures have been used to stabilize severely affected patients prior to surgical correction.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with <strong>unobstructed</strong> TAPVC generally have milder symptoms and require less intensive supportive care. However, patients with signs of pulmonary overcirculation (eg, tachypnea, respiratory distress, poor feeding) may require diuretic therapy (eg, <a class="drug drug_pediatric" data-topicid="13329" href="/d/drug information/13329.html" rel="external">furosemide</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical correction</strong> – The definitive treatment for TAPVC is surgical correction. The goal of surgery is to reestablish a direct pathway between the pulmonary veins and the left atrium, while avoiding obstruction of pulmonary venous drainage. The specific surgical procedure varies depending upon the anatomy of the TAPVC lesion. (See <a class="local">'Surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome</strong> – With improvements in medical management and surgical techniques, TAPVC has changed from a condition that was often fatal during infancy to having long-term survival rates of approximately 85 percent. Early mortality (death within 30 days of surgical correction) is &lt;10 percent. Approximately 10 to 15 percent of patients require reintervention. PVO in the pre- or postoperative setting is associated with increased risk of morbidity and mortality. (See <a class="local">'Natural history'</a> above and <a class="local">'Outcome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up care</strong> – After surgical repair, follow-up care should be individualized. In general, physical activity is not restricted and endocarditis prophylaxis is not indicated beyond six months after the surgery. Other important aspects of follow-up care include developmental screening and monitoring for arrhythmias. (See <a class="local">'Follow-up care'</a> above and  <a class="medical medical_review" href="/d/html/615.html" rel="external">"Developmental-behavioral surveillance and screening in primary care"</a> and  <a class="medical medical_review" href="/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Reller MD, Strickland MJ, Riehle-Colarusso T, et al. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr 2008; 153:807.</a></li><li><a class="nounderline abstract_t">Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002; 39:1890.</a></li><li><a class="nounderline abstract_t">Shi G, Zhu Z, Chen J, et al. Total Anomalous Pulmonary Venous Connection: The Current Management Strategies in a Pediatric Cohort of 768 Patients. Circulation 2017; 135:48.</a></li><li><a class="nounderline abstract_t">NEILL CA. Development of the pulmonary veins; with reference to the embryology of anomalies of pulmonary venous return. Pediatrics 1956; 18:880.</a></li><li><a class="nounderline abstract_t">CRAIG JM, DARLING RC, ROTHNEY WB. Total pulmonary venous drainage into the right side of the heart; report of 17 autopsied cases not associated with other major cardiovascular anomalies. Lab Invest 1957; 6:44.</a></li><li><a class="nounderline abstract_t">Duff DF, Nihill MR, McNamara DG. Infradiaphragmatic total anomalous pulmonary venous return. Review of clinical and pathological findings and results of operation in 28 cases. Br Heart J 1977; 39:619.</a></li><li><a class="nounderline abstract_t">Seale AN, Uemura H, Sethia B, et al. Total anomalous pulmonary venous connection to the supradiaphragmatic inferior vena cava. Ann Thorac Surg 2008; 85:1089.</a></li><li class="breakAll">Kirshborn P, Jaggers J, Underleider R. Total anomalous pulmonary venous connection. In: Pediatric Cardiac Surgery, 3rd ed, Mavroudis C (Ed), Mosby, Philadelphia 2003. p.612.</li><li class="breakAll">Keane JF, Fyler DC. Total anomalous pulmonary venous return. In: Nadas' Pediatric Cardiology, 2nd, Keane JF, Lock JE, Fyler DC (Eds), Saunders Elsevier, Philadelphia 2006. p.773.</li><li><a class="nounderline abstract_t">Seale AN, Uemura H, Webber SA, et al. Total anomalous pulmonary venous connection: morphology and outcome from an international population-based study. Circulation 2010; 122:2718.</a></li><li><a class="nounderline abstract_t">BURROUGHS JT, EDWARDS JE. Total anomalous pulmonary venous connection. Am Heart J 1960; 59:913.</a></li><li class="breakAll">Ward KE, Mullins CE. Anomalous pulmonary venous connections, pulmonary vein stenosis, and atresia of the common pulmonary vein. In: The Science and Practice of Pediatric Cardiology, Garson A Jr, Bricker JT, Fisher DJ, Neish SR (Eds), Williams and Wilkins, Baltimore 1998. p.1431.</li><li><a class="nounderline abstract_t">Karamlou T, Gurofsky R, Al Sukhni E, et al. Factors associated with mortality and reoperation in 377 children with total anomalous pulmonary venous connection. Circulation 2007; 115:1591.</a></li><li><a class="nounderline abstract_t">Gathman GE, Nadas AS. Total anomalous pulmonary venous connection: clinical and physiologic observations of 75 pediatric patients. Circulation 1970; 42:143.</a></li><li class="breakAll">van Praagh S. Cardiac malpositions and the heterotzxy syndromes. In: Nadas' Pediatric Cardiology, 2nd, Keane JF, Lock JE, Fyler DC (Eds), Saunders Elsevier, Philadelphia 2006. p.675.</li><li><a class="nounderline abstract_t">van der Velde ME, Parness IA, Colan SD, et al. Two-dimensional echocardiography in the pre- and postoperative management of totally anomalous pulmonary venous connection. J Am Coll Cardiol 1991; 18:1746.</a></li><li><a class="nounderline abstract_t">Seale AN, Carvalho JS, Gardiner HM, et al. Total anomalous pulmonary venous connection: impact of prenatal diagnosis. Ultrasound Obstet Gynecol 2012; 40:310.</a></li><li><a class="nounderline abstract_t">Domadia S, Kumar SR, Votava-Smith JK, Pruetz JD. Neonatal Outcomes in Total Anomalous Pulmonary Venous Return: The Role of Prenatal Diagnosis and Pulmonary Venous Obstruction. Pediatr Cardiol 2018; 39:1346.</a></li><li><a class="nounderline abstract_t">Kim TH, Kim YM, Suh CH, et al. Helical CT angiography and three-dimensional reconstruction of total anomalous pulmonary venous connections in neonates and infants. AJR Am J Roentgenol 2000; 175:1381.</a></li><li><a class="nounderline abstract_t">Choe YH, Lee HJ, Kim HS, et al. MRI of total anomalous pulmonary venous connections. J Comput Assist Tomogr 1994; 18:243.</a></li><li><a class="nounderline abstract_t">Shen Q, Pa M, Hu X, Wang J. Role of plain radiography and CT angiography in the evaluation of obstructed total anomalous pulmonary venous connection. Pediatr Radiol 2013; 43:827.</a></li><li class="breakAll">Geva T, van Praagh S. Anomalies of the pulmonary veins. In: Moss and Adams' heart disease in infants, children, and adolescents: including the fetus and young adult, 7th, Allen HD, Shaddy RE, Driscoll DJ, Feltes TF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. p.761.</li><li><a class="nounderline abstract_t">Ishino K, Alexi-Meskishvili V, Hetzer R. Preoperative extracorporeal membrane oxygenation in newborns with total anomalous pulmonary venous connection. Cardiovasc Surg 1999; 7:473.</a></li><li><a class="nounderline abstract_t">Raisher BD, Grant JW, Martin TC, et al. Complete repair of total anomalous pulmonary venous connection in infancy. J Thorac Cardiovasc Surg 1992; 104:443.</a></li><li><a class="nounderline abstract_t">Lock JE, Bass JL, Castaneda-Zuniga W, et al. Dilation angioplasty of congenital or operative narrowings of venous channels. Circulation 1984; 70:457.</a></li><li><a class="nounderline abstract_t">Meadows J, Marshall AC, Lock JE, et al. A hybrid approach to stabilization and repair of obstructed total anomalous pulmonary venous connection in a critically ill newborn infant. J Thorac Cardiovasc Surg 2006; 131:e1.</a></li><li><a class="nounderline abstract_t">Hancock Friesen CL, Zurakowski D, Thiagarajan RR, et al. Total anomalous pulmonary venous connection: an analysis of current management strategies in a single institution. Ann Thorac Surg 2005; 79:596.</a></li><li><a class="nounderline abstract_t">Sinzobahamvya N, Arenz C, Brecher AM, et al. Early and long-term results for correction of total anomalous pulmonary venous drainage (TAPVD) in neonates and infants. Eur J Cardiothorac Surg 1996; 10:433.</a></li><li><a class="nounderline abstract_t">Bando K, Turrentine MW, Ensing GJ, et al. Surgical management of total anomalous pulmonary venous connection. Thirty-year trends. Circulation 1996; 94:II12.</a></li><li><a class="nounderline abstract_t">Michielon G, Di Donato RM, Pasquini L, et al. Total anomalous pulmonary venous connection: long-term appraisal with evolving technical solutions. Eur J Cardiothorac Surg 2002; 22:184.</a></li><li><a class="nounderline abstract_t">Boger AJ, Baak R, Lee PC, et al. Early results and long-term follow-up after corrective surgery for total anomalous pulmonary venous return. Eur J Cardiothorac Surg 1999; 16:296.</a></li><li><a class="nounderline abstract_t">Caldarone CA, Najm HK, Kadletz M, et al. Surgical management of total anomalous pulmonary venous drainage: impact of coexisting cardiac anomalies. Ann Thorac Surg 1998; 66:1521.</a></li><li><a class="nounderline abstract_t">Jenkins KJ, Sanders SP, Orav EJ, et al. Individual pulmonary vein size and survival in infants with totally anomalous pulmonary venous connection. J Am Coll Cardiol 1993; 22:201.</a></li><li><a class="nounderline abstract_t">Frommelt PC, Sheridan DC, Deatsman S, et al. Unobstructive total anomalous pulmonary venous return: impact of early elective repair on the need for prolonged mechanical ventilatory support. Pediatr Cardiol 2010; 31:1191.</a></li><li><a class="nounderline abstract_t">St Louis JD, Harvey BA, Menk JS, et al. Repair of "simple" total anomalous pulmonary venous connection: a review from the Pediatric Cardiac Care Consortium. Ann Thorac Surg 2012; 94:133.</a></li><li><a class="nounderline abstract_t">Duff JP, Joffe AR, Vatanpour S, et al. Neurocognitive outcomes at kindergarten entry after surgical repair of total anomalous pulmonary venous connection in early infancy. Pediatr Cardiol 2015; 36:350.</a></li><li><a class="nounderline abstract_t">Hyde JA, Stümper O, Barth MJ, et al. Total anomalous pulmonary venous connection: outcome of surgical correction and management of recurrent venous obstruction. Eur J Cardiothorac Surg 1999; 15:735.</a></li><li><a class="nounderline abstract_t">Saxena A, Fong LV, Lamb RK, et al. Cardiac arrhythmias after surgical correction of total anomalous pulmonary venous connection: late follow-up. Pediatr Cardiol 1991; 12:89.</a></li><li><a class="nounderline abstract_t">Tanel RE, Kirshbom PM, Paridon SM, et al. Long-term noninvasive arrhythmia assessment after total anomalous pulmonary venous connection repair. Am Heart J 2007; 153:267.</a></li><li><a class="nounderline abstract_t">Kirshbom PM, Flynn TB, Clancy RR, et al. Late neurodevelopmental outcome after repair of total anomalous pulmonary venous connection. J Thorac Cardiovasc Surg 2005; 129:1091.</a></li><li><a class="nounderline abstract_t">Marino BS, Lipkin PH, Newburger JW, et al. Neurodevelopmental outcomes in children with congenital heart disease: evaluation and management: a scientific statement from the American Heart Association. Circulation 2012; 126:1143.</a></li></ol></div><div id="topicVersionRevision">Topic 5767 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18657826" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12084585" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The incidence of congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27881562" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Total Anomalous Pulmonary Venous Connection: The Current Management Strategies in a Pediatric Cohort of 768 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13378917" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Development of the pulmonary veins; with reference to the embryology of anomalies of pulmonary venous return.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13386206" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Total pulmonary venous drainage into the right side of the heart; report of 17 autopsied cases not associated with other major cardiovascular anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/884012" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Infradiaphragmatic total anomalous pulmonary venous return. Review of clinical and pathological findings and results of operation in 28 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18291209" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Total anomalous pulmonary venous connection to the supradiaphragmatic inferior vena cava.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18291209" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Total anomalous pulmonary venous connection to the supradiaphragmatic inferior vena cava.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18291209" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Total anomalous pulmonary venous connection to the supradiaphragmatic inferior vena cava.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21135364" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Total anomalous pulmonary venous connection: morphology and outcome from an international population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13806293" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Total anomalous pulmonary venous connection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13806293" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Total anomalous pulmonary venous connection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17353446" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Factors associated with mortality and reoperation in 377 children with total anomalous pulmonary venous connection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5425587" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Total anomalous pulmonary venous connection: clinical and physiologic observations of 75 pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5425587" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Total anomalous pulmonary venous connection: clinical and physiologic observations of 75 pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1960324" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Two-dimensional echocardiography in the pre- and postoperative management of totally anomalous pulmonary venous connection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22262371" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Total anomalous pulmonary venous connection: impact of prenatal diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29796693" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Neonatal Outcomes in Total Anomalous Pulmonary Venous Return: The Role of Prenatal Diagnosis and Pulmonary Venous Obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11044048" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Helical CT angiography and three-dimensional reconstruction of total anomalous pulmonary venous connections in neonates and infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8126275" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : MRI of total anomalous pulmonary venous connections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23341089" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Role of plain radiography and CT angiography in the evaluation of obstructed total anomalous pulmonary venous connection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23341089" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Role of plain radiography and CT angiography in the evaluation of obstructed total anomalous pulmonary venous connection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430534" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Preoperative extracorporeal membrane oxygenation in newborns with total anomalous pulmonary venous connection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1495308" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Complete repair of total anomalous pulmonary venous connection in infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6235060" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Dilation angioplasty of congenital or operative narrowings of venous channels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16580428" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A hybrid approach to stabilization and repair of obstructed total anomalous pulmonary venous connection in a critically ill newborn infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15680843" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Total anomalous pulmonary venous connection: an analysis of current management strategies in a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8817139" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Early and long-term results for correction of total anomalous pulmonary venous drainage (TAPVD) in neonates and infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8901712" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Surgical management of total anomalous pulmonary venous connection. Thirty-year trends.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12142183" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Total anomalous pulmonary venous connection: long-term appraisal with evolving technical solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10554847" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Early results and long-term follow-up after corrective surgery for total anomalous pulmonary venous return.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9875745" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Surgical management of total anomalous pulmonary venous drainage: impact of coexisting cardiac anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8509542" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Individual pulmonary vein size and survival in infants with totally anomalous pulmonary venous connection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20848277" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Unobstructive total anomalous pulmonary venous return: impact of early elective repair on the need for prolonged mechanical ventilatory support.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22560965" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Repair of "simple" total anomalous pulmonary venous connection: a review from the Pediatric Cardiac Care Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25208496" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Neurocognitive outcomes at kindergarten entry after surgical repair of total anomalous pulmonary venous connection in early infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10431851" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Total anomalous pulmonary venous connection: outcome of surgical correction and management of recurrent venous obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1866343" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cardiac arrhythmias after surgical correction of total anomalous pulmonary venous connection: late follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17239688" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Long-term noninvasive arrhythmia assessment after total anomalous pulmonary venous connection repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15867785" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Late neurodevelopmental outcome after repair of total anomalous pulmonary venous connection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22851541" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Neurodevelopmental outcomes in children with congenital heart disease: evaluation and management: a scientific statement from the American Heart Association.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
